Best Stocks: Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), INSYS Therapeutics, Inc. (NASDAQ:INSY), City Office Reit, Inc. (NYSE:CIO), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Grupo Simec (NYSEMKT:SIM)

Ohr Pharmaceutical (NASDAQ: OHRP) announced that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company’s sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company’s board of directors.Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) belongs to Healthcare sector. Its weekly performance is -22.55%. On last trading day company shares ended up $2.37. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -15.44%.

On 6 August, INSYS Therapeutics, Inc. (NASDAQ:INSY) reported Net income for the second quarter of 2015 was $7.3 million, or $0.10 per basic and diluted share, compared to net income of $9.5 million, or $0.14 per basic and $0.13 per diluted share, for the second quarter of 2014. Non-GAAP adjusted net income for the second quarter of 2015 was $15.6 million, or $0.21 per diluted share, compared to non-GAAP adjusted net income of $20.9 million, or $0.29 per diluted share, in the prior year quarter.INSYS Therapeutics, Inc. (NASDAQ:INSY) shares fell -3.92% in last trading session and ended the day at $37.53. INSY Gross Margin is 90.40% and its return on assets is 19.10%. INSYS Therapeutics, Inc. (NASDAQ:INSY) quarterly performance is 27.07%.

On 6 August, City Office Reit, Inc. (NYSE:CIO) reported Core FFO was $4.2 million or $0.27 per fully diluted share. AFFO was $3.3 million or $0.21 per fully diluted share. Adding back the leasing commissions associated with the previously announced 178,330 square foot lease completed during the quarter with D&B results in a normalized AFFO of $4.1 million, or $0.26 per fully diluted share. Net loss attributable to the Company for the three months ended June 30, 2015 was $1.8 million, or ($0.15) per share. On 11 August, City Office Reit, Inc. (NYSE:CIO) shares fell -0.51% and was closed at $11.74. City Office Reit, Inc. (NYSE:CIO) year to date (YTD) performance is -4.83%.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) loss from operations was $4.8 million and $3.5 million for the three months ended June 30, 2015 and 2014, respectively. Rexahn’s net loss was $3.2 million, or $0.02 per share, for the three months ended June 30, 2015, compared to a net income of $0.2 million, or $0.00 per share, for the three months ended June 30, 2014. For the six month period ending June 30, 2015, Rexahn’s net loss was $7.5 million, or $0.04 per share compared to $14.4 million or $0.08 per share for the same period in 2014. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ended the last trading day at $0.56. Company weekly volatility is calculated as 6.01% and price to cash ratio as 3.41. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) showed a weekly performance of -3.45%.

Zacks upgraded shares of Grupo Simec SAB de CV (NYSEMKT:SIM) from a sell rating to a hold rating in a research note issued to investors on Friday, MarketBeat reports.Grupo Simec S.A.B. de C.V. (NYSEMKT:SIM) shares fell -2.22% in last trading session and ended the day at $8.82. SIM Gross Margin is 6.20% and its return on assets is 4.60%. Grupo Simec S.A.B. de C.V. (NYSEMKT:SIM) quarterly performance is 1.38%.

Leave a Reply

Your email address will not be published. Required fields are marked *